

AACR 2023 Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved

September 29-October 2, 2023

C139: Robustness of a Targeted Methylation-Based Multi-Cancer Early Detection (MCED) Test to Population Differences in Self-Reported Ethnicity

Oliver Venn, PhD,^{1*} Joerg Bredno, PhD,^{1*} Alexis Thornton, PhD,¹ Christopher Chang, PhD,¹ Earl Hubbell, PhD,¹ Kathryn Kurtzman, MD,¹ John Beausang, PhD,¹ Charles Swanton, MBPhD, FRS^{2,3}

¹GRAIL, LLC, Menlo Park, California, USA; ²Francis Crick Institute, London, UK; ³UCL Cancer Institute, CRUK Lung Cancer Centre of Excellence, London, UK

*Contributed equally

Disclosures

Study funded by GRAIL, LLC. OV, JBr, AT, CC, EH, KK, JBe are current employees of GRAIL, LLC, with equity in the company. CS reports grant support from AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer, Roche-Ventana, Invitae (previously Archer Dx Inc), and Ono Pharmaceutical; is an AstraZeneca Advisory Board member and Chief Investigator for the AstraZeneca MeRmaid 1 and 2 clinical trials and is also Co-Chief Investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL's Scientific Advisory Board (SAB); reports consultant fees from Achilles Therapeutics (also SAB member), Bicycle Therapeutics (also a SAB member), Genentech, Medicxi, Roche Innovation Centre – Shanghai, Metabomed, and the Sarah Cannon Research Institute; reports honoraria from Amgen, AstraZeneca, Pfizer, Novartis, GlaxoSmithKline, Merck Sharp & Dohme, Bristol Myers Squibb, Illumina, and Roche-Ventana; had stock options in Apogen Biotechnologies and GRAIL until June 2021, and currently has stock options in Epic Bioscience, Bicycle Therapeutics, and Achilles Therapeutics; and is a co-founder of Achilles Therapeutics; holds patents relating to assay technology to detect tumour recurrence (PCT/GB2017/053289), targeting neoantigens (PCT/EP2016/059401), identifying patent response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), and identifying patients who respond to cancer treatment (PCT/GB2018/051912); holds US patent relating to detecting tumour mutations (PCT/US2017/28013), methods for lung cancer detection (US20190106751A1); and holds both a European and US patent related to identifying insertion/deletion mutation targets (PCT/GB2018/051892). CS is a Royal Society Napier Research Professor (RSRP\R\210001) and has received funding from the Francis Crick Institute that receives its core funding from Cancer Research UK (CC2041), the UK Medical Research Council (CC2041), and the Wellcome Trust (CC2041); Cancer Research UK (TRACERx [C11496/A17786], PEACE [C416/A21999], and CRUK Cancer Immunotherapy Catalyst Network); Cancer Research UK Lung Cancer Centre of Excellence (C11496/A30025); the Rosetrees Trust, Butterfield and Stoneygate Trusts; NovoNordisk Foundation (ID16584); Royal Society Professorship Enhancement Award (RP/EA/180007); National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre; the Cancer Research UK-University College London Centre; Experimental Cancer Medicine Centre; the Breast Cancer Research Foundation (US) (BCRF-22-157); Cancer Research UK Early Detection and Diagnosis Primer Award (Grant EDDPMA-Nov21/100034); The Mark Foundation for Cancer Research Aspire Award (Grant

21-029-ASP); Stand Up To Cancer-LUNGeivity American Lung Association Lung Cancer Interception Dream Team Translational Research Grant (Grant Number: SU2C-AACR-DT23-17); and an ERC Advanced Grant (PROTEUS) from the European Research Council under the European Union's Horizon 2020 research and innovation programme (grant agreement no. 835297).